Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Tvardi Therapeutics, Inc. (TVRD) is a privately held, clinical-stage biopharmaceutical company focused on developing precision therapies for fibrotic diseases and cancer driven by dysregulated transcriptional signaling. The company operates within the biotechnology and life sciences industries, with a specific emphasis on targeting Signal Transducer and Activator of Transcription (STAT) pathways, particularly STAT3 and STAT5, which are implicated in multiple severe and underserved diseases.
The company’s core value proposition lies in its development of small-molecule transcription factor inhibitors, an area historically considered difficult to drug. Tvardi’s lead programs target diseases with high unmet medical need, including idiopathic pulmonary fibrosis (IPF), other fibrotic lung diseases, and certain oncologic indications. Tvardi Therapeutics was founded in 2017 and emerged from academic research, with its scientific foundation rooted in discoveries related to STAT signaling in fibrosis and cancer.
Business Operations
Tvardi Therapeutics’ operations are centered on research and development, with revenue generation not yet established as the company remains in the clinical development stage. Its primary business activities involve advancing proprietary drug candidates through preclinical and clinical trials, regulatory engagement, and translational research. The company’s lead asset, TTI-101, is an oral, small-molecule inhibitor of STAT3 currently being evaluated in clinical trials for fibrotic lung diseases and select cancers.
The company operates primarily within the United States and relies on a combination of internal scientific teams and external partnerships, including contract research organizations (CROs) and academic collaborators, to conduct clinical trials and supporting studies. Tvardi does not report commercial products, material subsidiaries, or revenue-generating joint ventures based on available public disclosures.
Strategic Position & Investments
Tvardi Therapeutics’ strategy is centered on becoming a leader in transcription factor-targeted therapeutics, particularly within fibrosis, an area with limited effective treatment options. The company’s growth initiatives focus on advancing TTI-101 through mid-stage clinical development while expanding its pipeline of STAT-focused compounds for additional fibrotic and oncologic indications.
The company has raised capital through multiple private financing rounds from venture capital and institutional life science investors. While specific investment amounts and ownership structures vary across disclosures, Tvardi has consistently positioned itself as a platform-based company leveraging STAT biology. Data inconclusive based on available public sources regarding any completed acquisitions or the existence of independently operating subsidiaries.
Geographic Footprint
Tvardi Therapeutics is headquartered in the United States, with its principal offices located in Texas. Its operational footprint is primarily domestic, with clinical trial activities conducted at multiple investigational sites across North America. There is no verified public information indicating permanent operational facilities outside the United States.
International exposure is currently limited to potential future clinical development and regulatory pathways rather than established commercial or research operations abroad. Any global expansion remains prospective and dependent on clinical outcomes and strategic partnerships.
Leadership & Governance
Tvardi Therapeutics is led by an executive team with experience in biotechnology development, clinical research, and company formation. The leadership emphasizes a science-driven and patient-focused approach, prioritizing rigorous clinical validation and targeted therapeutic design.
Key executives include:
- Imran Saeed – Chief Executive Officer
- Andrew M. Dudley, PhD – Chief Scientific Officer
- Susan Schorr – Chief Financial Officer
- Jonathan Rigby, MD – Chief Medical Officer
The company was founded by Lynn Cornelius, MD, whose academic and clinical research in STAT signaling helped shape Tvardi’s scientific direction. Governance is supported by a board of directors composed of company leadership and investor representatives. Data inconclusive based on available public sources regarding detailed board committee structures or formal governance policies beyond standard private-company practices.